Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
Here is some other vaccine news of note for the week.
Moderna unveiled two phase 1 prophylactic vaccine programs and a new Chikungunya antibody candidate at JPM.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
China's ApolloBio increased upfront payment, while also terminating its right to buy into Inovio.
Sanofi's recent loss in C. diff is a win for Pfizer and Valneva, which boast their own late-stage candidates, according to GlobalData.
Here's some other vaccine news of note for the week.
VBI Vaccines is aiming for 2019 approval filings for its hepatitis B vaccine if a head-to-head trial against GSK's entrenched Engerix-B succeeds.
Philippines' health secretary plans to ask Sanofi for a Dengvaxia refund and to sue the drugmaker amid worries about the dengue shot's safety.
Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.
Immunovaccine showed that its cancer vaccine, when paired with Incyte's epacadostat, might work in ovarian cancer.